← All articles

5-Amino-1MQ Research: NNMT, Metabolism and Evidence Limits

Bookmark this page

Save this article in your browser so you can find it again:

  • Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
  • iPhone or iPad: In Safari, tap Share, then Add Bookmark.
  • Android: In Chrome, open the menu and tap the star.

Other browsers may use a different menu.

5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase, or NNMT. It is not a peptide. Its research story concerns an enzyme, cellular metabolism and experimental animal outcomes. Those are useful subjects, but they do not establish a human weight-loss treatment or a predictable personal result. Original compound study

At a glance:

  • A study of NNMT knockdown is different from a study supplying 5-amino-1MQ.

  • Changes in a cell's NAD+ measurements are not proof of more energy in people.

  • Animal studies contain both favorable findings and unchanged outcomes.

  • A substance identifier, research label or purity result does not establish clinical approval.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted summary is not an independent scientific review. Selected sources were checked November 11, 2026; access limits appear below.

5-Amino-1MQ evidence map separates NNMT target biology, compound experiments and the limits of human observational datasets.
Selected cell and animal studies support research questions. They do not establish human efficacy or a known long-term safety profile for 5-amino-1MQ.

1. What does NNMT do, and why study its inhibition?

NNMT transfers a methyl group from S-adenosylmethionine, or SAM, to nicotinamide. Nicotinamide also participates in pathways that regenerate NAD+, a coenzyme involved in metabolism. This connects NNMT research with both methyl-group handling and NAD+ biology; it does not make NNMT inhibition equivalent to taking an NAD+ precursor. Kraus and colleagues, 2014

In that study, reducing Nnmt expression in mouse fat and liver protected against diet-induced obesity and changed energy-expenditure and metabolic measurements. The intervention reduced expression of the target rather than testing 5-amino-1MQ as a human medicine. A target can be biologically interesting before any particular inhibitor has established clinical usefulness.

This distinction prevents a common citation error: collecting every favorable NNMT paper under one compound's name. A genetic intervention, a different inhibitor and a specific quinolinium compound may differ in selectivity, distribution and exposure. The question is not simply whether the paper mentions NNMT, but what the researchers actually changed.

Our NAD+, NMN and NR comparison explains why related metabolic pathways do not make different molecules interchangeable.

2. What did the original 5-amino-1MQ experiment show?

Neelakantan and colleagues studied cells and mice with diet-induced obesity. In the 11-day mouse experiment, nine animals per group received the compound or control. Treated mice lost about 5.1% of starting body weight, while controls gained about 1.4%; measured food intake did not differ significantly. These are short-term mouse findings, not a human results timeline. Original report, section 3.7 and Figure 5

The cellular results also require precision. The overall statistical test for the NAD+ measurements did not reach the usual significance threshold, although one concentration-specific comparison did. Higher concentrations raised cell-viability concerns. Neither “reliably raises NAD+ everywhere” nor “has no toxicity” accurately captures that experiment. Original report, sections 3.2–3.5

Research evidence map

Evidence

Actual intervention or setting

Useful boundary

Kraus, 2014

Nnmt knockdown in mice and cell experiments

Supports investigation of the target; does not test this compound in people

Neelakantan, 2018

5-amino-1MQ in cells and diet-induced-obesity mice

Short animal experiment, with assay-specific results

Dong, 2025

Human muscle datasets plus an NNMT-inhibitor mouse experiment

Observational human material is separate from the treated animals

3. What do newer muscle findings add?

The 2025 report examined existing muscle datasets from people with peripheral artery disease and conducted a separate mouse experiment involving reduced limb blood flow. The human data showed elevated NNMT measurements; those patients were not treated with the inhibitor in this study. In mice, selected muscle-strength and work measurements improved, but blood-flow recovery, capillary density, muscle mass and fiber size did not. A trend toward less necrosis was not statistically significant. Dong and colleagues, original abstract

The methods identify the reagent as NNMTi, catalog HY-131042. That identifier maps to 5-amino-1-methylquinolinium iodide in the PubChem substance record. This clarifies the reported reagent; it does not verify any retailer's vial. The paper's abstract and methods also give different mouse totals, so a single definitive sample count should not be copied without clarification. Original methods, sections 2.3–2.5

The practical lesson is that better performance on one experimental measurement can coexist with unchanged tissue or circulation measurements. It would be misleading to compress these findings into “restores circulation,” “builds muscle,” or a disease-treatment claim for people.

4. What human evidence and regulatory conclusions are justified?

On November 11, 2026, exact-name ClinicalTrials.gov searches for “5-amino-1MQ” and “5-amino-1-methylquinolinium” returned no records. The selected original reports reviewed here did not establish human intervention efficacy. That is a bounded search result, not proof that every unpublished, unregistered or differently named study has been excluded. ClinicalTrials.gov compound search

FDA's substance registry lists the iodide form under UNII K9G33W2TTZ. The registry explicitly explains that having a UNII does not imply regulatory review or approval. A chemical identity entry should therefore never be presented as an approved treatment. This guide does not make a comprehensive legal determination about supply or compounding. FDA substance record

There is also a difference between missing clinical evidence and demonstrated safety. Without suitable human studies, the selected animal findings cannot supply a dependable frequency of side effects, an effective clinical exposure or a long-term safety profile.

5. Which questions should the next study answer?

A useful next study would identify the exact chemical form and establish exposure and target engagement before interpreting a downstream result. It would distinguish weight, fat distribution, muscle function and patient experience rather than treating them as one outcome. Relevant comparators and systematic harms collection would be necessary to assess whether any observed change matters clinically.

For an existing paper, ask whether the intervention was the same compound, whether the result was prespecified, and whether unchanged outcomes receive equal attention. Our study-reading guide provides a practical framework. For a separate question about supplied material, the COA methods guide explains why identity and purity tests cannot replace clinical evidence.

Source-access scope, November 11, 2026: Original abstracts, selected full-text results from the 2018 paper, selected methods from the 2025 paper, official identity records and the two registry searches were checked. This was not a systematic review or a reanalysis of datasets. No stock lot was authenticated. Catalog materials are for lawful laboratory research, not human or veterinary use.